Prostanoids



Included Products: Orenitram (treprostanil), Remodulin (treprostanil), Tyvaso (treprostanil), Tyvaso DPI (treprostanil), Veletri (epoprostanil)

Created: 04/28/2010

Revised: 09/08/2022

Reviewed: 11/10/2022

Updated: 12/01/2022

Ρι	Pulmonary Arterial Hypertension				
Initial Criteria		lf yes	lf no		
1.	Is medication being requested by a pulmonologist or cardiologist?	Continue to #2.	Do not approve.		
2.	Does the member have a diagnosis of pulmonary arterial hypertension WHO Group 1 diagnosed by right heart catheterization?	Continue to #6.	Continue to #3.		
3.	Does the member have a diagnosis of WHO Group 3 pulmonary hypertension diagnosed by right heart catheterization?	Continue to #4.	Do not approve.		
4.	Does the member meet all the inclusion criteria for the "INCREASE" trial?	Continue to #5.	Do not approve.		
	Evidence of diffuse parenchymal lung disease				
	Baseline 6MWD ≥100 meters				
	Baseline FVC <70%				
	No other PH diagnosis other than WHO Group 3 PH-ILD				
5.	Has the request been reviewed by internal medical director or Oregon Clinic Specialist?	Continue to #10.	Do not approve.		
6.	Is the member currently on, has a failure or contraindication to, or is concurrently being prescribed 1) sildenafil or tadalafil and 2) bosentan or ambrisentan?	Continue to #7.	Pend for documentation of why sildenafil/tadalafil and bosentan/ambrisentan is not being used.		

2.	Approve for 12 months.		
1.	Is documentation provided showing the member is still being seen by the pulmonologist or cardiologist and has been adherent to therapy?	Continue to #2.	Do not approve.
Renewal Criteria		If yes	lf no
10.	Approve for 12 months.		
9.	Is there documentation that inhaled therapy is medically necessary?	Continue to #10.	Do not approve and offer Veletri.
8.	Is there documentation of a reason that oral therapy is preferred?	Continue to #10.	Do not approve and offer Veletri.
7.	Which drug is being requested?a. Veletri or Remodulin, continue to #10.b. Orenitram, continue to #8.c. Tyvaso, continue to #9.		